{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-035909","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.959324+00:00","generated_at":"2026-05-25T01:55:35.068855+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Design Therapeutics Q4 2024 net loss $13.7M; cash $245.5M; FA and FECD trials advancing","bullets":["Net loss of $13.7M for Q4 2024 and $49.6M for full year 2024; R&D expense $44.4M, G&A $18.0M.","Cash, equivalents and securities $245.5M as of Dec 31, 2024; expected funding into 2029.","FA program: Phase 1 single ascending dose trial of DT-216P2 initiated; patient dosing expected mid-2025.","FECD program: DT-168 Phase 1 dosing complete; data on track for H1 2025; observational study enrolled ~250 patients.","DM1 development candidate selection expected in 2025; HD preclinical work ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-035909","json":"https://secwatch.observer/filing/0000950170-25-035909.json","markdown":"https://secwatch.observer/filing/0000950170-25-035909.md","text":"https://secwatch.observer/filing/0000950170-25-035909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017025035909/0000950170-25-035909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017025035909/dsgn-20250310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:55:35.068855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}